Techniclone International announced it has received U.S. PatentNo. 5,194,594 for modified antibodies.

The antibodies have been chemically altered for superiortumor uptake and shorter blood clearance time.

Lon Stone, chairman and chief executive officer of the Tustin,Calif., company (NASDAQ:TCLN), said the antibodies shouldimprove both diagnostic imaging and therapeutic capabilities.

The modified antibodies showed two to three times greatertumor uptake, the company said. They also exhibit clearanceprofiles similar to monoclonal antibody fragments and causeless toxicity than conventional antibodies and antibodyfragments.

(c) 1997 American Health Consultants. All rights reserved.